Posted by Michael Wonder on 11 Feb 2022
Health economic assessment of Adakveo for the treatment of sickle cell anaemia
11 February 2022 - Adakveo is used to prevent recurrent so-called vaso-occlusive crises in patients from 16 years of age who have sickle cell anaemia.
TLV considers that the relevant comparison alternative is not a supplement to standard treatment, as Adakveo will be used as a supplement to the treatment that the patient has to prevent vaso-occlusive crises.
